1. AbbVie announces $70 million expansion in Massachusetts for biologics manufacturing. 2. Expansion supports production of oncology and immunology medicines. 3. The investment is part of AbbVie's $10 billion U.S. commitment. 4. New jobs will be created at the Worcester facility. 5. The expansion aims to meet growing global demand for biologics.
The expansion increases AbbVie's production capabilities, which could lead to future revenue growth, similar to past successful expansions that positively affected stock prices.
The article highlights significant investment in manufacturing, key for AbbVie's growth trajectory and stock performance.
The expansion's effect on revenue and market position will unfold over several years; past examples show that infrastructure investments generally support long-term growth.
NORTH CHICAGO, Ill., Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass., which serves as a center of excellence for biologics research and development and manufacturing. This expansion is part of the company's previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand critical biologics manufacturing capabilities and capacity.
This investment will further expand AbbVie's domestic biologics manufacturing capacity to meet increased global demand and support U.S. production of current and next-generation oncology and immunology medicines. It will include construction of additional biologics manufacturing areas and a three-story building housing laboratory, warehouse and office space. Construction will enable the expedited transfer of select oncology products from Europe to the U.S.
"For more than three decades, ABC has been at the forefront of scientific innovation and biologics manufacturing," said Azita Saleki-Gerhardt, Ph.D., executive vice president and chief operations officer, AbbVie. "This investment will further expand AbbVie's biologics manufacturing capacity and position ABC to build upon its impressive track record of developing, manufacturing and launching next-generation complex biologic medicines that improve the lives of millions of patients worldwide."
With a presence in all 50 states and Puerto Rico, AbbVie employs 28,000 people in the U.S., including more than 2,000 in Massachusetts. This expansion will create new jobs at the ABC site and add additional capabilities to AbbVie's U.S. manufacturing footprint, which supports more than 6,000 American jobs across 11 manufacturing sites.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.
Media: Gabby Tarbert | Investors: Liz Shea (847) 935-2211 |
View original content:https://www.prnewswire.com/news-releases/abbvie-begins-construction-on-70-million-expansion-to-further-increase-biologics-manufacturing-and-rd-presence-in-the-us-302571294.html
SOURCE AbbVie